Results 191 to 200 of about 79,234 (256)

Selective Targeting of Immune Checkpoints HLA‐G and CD47 Using Novel Dual Signaling Protein DSP216 Promotes Innate Anticancer Immunity

Advanced Science, Volume 13, Issue 35, 24 June 2026.
The inhibitory immune checkpoints HLA‐G and CD47 are expressed on certain tumor types and inhibit immune cells in the tumor microenvironment. DSP216 binds specifically to cancer cells expressing both HLA‐G and CD47, and blocks their inhibitory signaling.
Lisa J. Jacob, Liat Tamir, Mufeed Abdeen, Ami Tamir, Alexandra Aronin, Itai Bloch, Roy Kahn, Iris Pecker, Mark Tykocinski, Gerwin Huls, Yaron Pereg, Ayelet Chajut, Edwin Bremer   +12 more
wiley   +1 more source

Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy

Advanced Science, Volume 13, Issue 35, 24 June 2026.
Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu, Mengtao Sun, Lusheng Li, Jieqiong Wang, Shibiao Wan   +4 more
wiley   +1 more source

An Engineered Nano-Bridging Strategy Remodels the Immune Microenvironment of Esophageal Squamous Cell Carcinoma via STING Pathway Activation. [PDF]

MedComm (2020)
Huang C, Tang X, Zhao Y, Xu D, Sun C, Wang C, Xie F, Xu F, Luo C, Zhang L, Wang Q.   +10 more
europepmc   +1 more source

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives

Advanced Science, Volume 13, Issue 35, 24 June 2026.
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård, Tatiana Bobrova, Amalie Leinebø, Thibault Leray, Shayamita Ghosh, Lorena García‐Hevia, Chiara Puccinelli, Lorenzo Riccio, Jacopo Sorani, Davide Bonifazi, Julien Caumartin, Emmanuel Donnadieu, Florence Gazeau, Roland Hischier, Else Marit Inderberg, Mónica L. Fanarraga, Maria Loustau, Bernd Nowack, Sébastien Wälchli, Cécilia Ménard‐Moyon   +19 more
wiley   +1 more source

Prior Cancer and Survival in Patients With Esophageal Squamous Cell Carcinoma.

JAMA Netw Open
Yu S, Hong JT, Jung HK, Lee HA, Jeong ES, Lee H, Don Choi K, Jung HY, Park JC, Kwon JG, Choi YJ, Hong SJ, Sung J, Chung WC, Kim KB, Kim SY, Song KH, Park KS, Jeon SW, Kim BW, Ryu HS, Lee OJ, Baik GH, Kim YS.   +23 more
europepmc   +1 more source

Esophageal squamous cell carcinoma in a patient with spinal cord injury complicated by achalasia: a case report. [PDF]

Front Oncol
Zhang Y, Li X.
europepmc   +1 more source

Nucleic Acid Therapeutics for “Undruggable” Cancer Targets: Mechanisms, Challenges, and Prospects

Advanced Science, Volume 13, Issue 36, 29 June 2026.
Nucleic acid therapeutics bypass the structural limitations of conventional drugs by targeting mRNA rather than proteins. This review examines how antisense oligonucleotides, siRNAs, miRNAs, aptamers, and mRNA vaccines intervene against historically undruggable oncoproteins including Ras, MYC, and p53, highlighting mechanistic advances, delivery ...
Feng Xu, Ke Wang, Kaizhong Lu, Tianlun Hou, Yuan Chen, Xian Wang, Hongchuan Jin   +6 more
wiley   +1 more source

Radiation-Based Multimodal Strategies for Esophageal Squamous Cell Carcinoma: From Definitive Chemoradiotherapy to Salvage Treatment. [PDF]

Cancers (Basel)
Taniyama Y, Jingu K, Sato C, Okamoto H, Ozawa Y, Ishida H, Ujiie N, Unno M, Kamei T.   +8 more
europepmc   +1 more source

Advances in Cancer Immunotherapy for Solid Tumors

Advanced Science, Volume 13, Issue 35, 24 June 2026.
Cancer immunotherapy for solid tumors is rapidly evolving beyond classical checkpoint blockade toward more precise strategies. Emerging checkpoint targets, bispecific antibodies, antibody–drug conjugate combinations, personalized vaccines, cellular therapies, and engineered cytokines are expanding therapeutic possibilities, while biomarker‐guided ...
Shira Gabizon‐Peretz, Harriet M. Kluger   +1 more
wiley   +1 more source

Commentary: Balancing Upfront Surgery and Neoadjuvant Therapy in Clinically Node-Negative T2-3 Esophageal Squamous Cell Carcinoma. [PDF]

J Chest Surg
Jeon JH.
europepmc   +1 more source